Cephalon Will Not Seek Gabitril Anxiety Indication In The Near-Term
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial evaluating tiagabine for treatment of generalized anxiety disorder did not meet primary endpoints.
You may also be interested in...
Gabitril Generalized Anxiety Disorder Filing Anticipated Mid-Year
Cephalon expects the results of Phase III studies supporting the anti-seizure medication for generalized anxiety will be available in Q2.
Gabitril Non-Epileptic Seizures Subject Of Bolded Warning
Bolded warning suggests dosing may have been factor in onset of seizures, and reminds physicians that Gabitril should be used as adjunct therapy in order to lower the drug's blood plasma levels. Cephalon CEO downplays effect of warning, noting similar warnings in antidepressant labeling.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.